ABL Bio Inc. (KOSDAQ: 298380), a clinical-stage biotech company developing bispecific antibody technology for immuno-oncology ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...

DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic planning, meticulous design, efficient ...

Cango Inc. ("Cango" or the "Company"), a rapidly expanding leader in Bitcoin mining, announced its production update for its crypto mining business for March 2025, highlighting significant growth in ...

今日（3月26日），基石药业宣布，其5款自主研发创新药物的最新临床前研究成果将同时亮相2025年美国癌症研究协会（AACR）年会，包括 三抗 CS2009、 双抗 CS2011及 三款创新抗体偶联药物（ADC） CS5006、CS5007与CS5005。相关研究摘要将于美国东部时间4月11日发表于AACR官方期刊 Cancer Research。

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called ...

Zura Bio Limited (NASDAQ:ZURA – Get Free Report) has been given an average rating of “Buy” by the eight brokerages that are currently covering the firm, MarketBeat reports. One analyst has rated the ...